Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Pipeline Review, H1 2018

  • ID: 4464924
  • Report
  • 45 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Eisai Co Ltd
  • Eli Lilly and Co
  • Ono Pharmaceutical Co Ltd
  • RaQualia Pharma Inc
  • Rottapharm Biotech Srl
  • MORE
Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Pipeline Review, H1 2018

Summary:

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Prostaglandin E2 receptor 4 (EP4) is a prostaglandin receptor encoded by the PTGER4 gene. The activity of the receptor is mediated by G proteins that stimulate adenylate cyclase. It has a relaxing effect on smooth muscle. It plays an important role in regulating renal hemodynamics, intestinal epithelial transport, adrenal aldosterone secretion, and uterine function.

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) pipeline Target constitutes close to 10 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 4, 2 and 3 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Central Nervous System, Gastrointestinal, Dermatology, Metabolic Disorders, Respiratory and Women's Health which include indications Autoimmune Disorders, Breast Cancer, Allergies, Chronic Pain, Contact Dermatitis, Inflammatory Bowel Disease, Non-Small Cell Lung Cancer, Osteoarthritis Pain, Acute Pain, Bladder Cancer, Cervical Cancer, Chronic Obstructive Pulmonary Disease (COPD), Colorectal Cancer, Endometriosis, Epithelial Ovarian Cancer, Gastrointestinal Tract Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hepatocellular Carcinoma, Inflammatory Pain, Lung Cancer, Osteoporosis, Pancreatic Cancer, Post-Operative Pain, Prostate Cancer, Rectal Cancer, Renal Cell Carcinoma, Rheumatoid Arthritis, Solid Tumor and Ulcerative Colitis.

The latest report Prostaglandin E2 Receptor EP4 Subtype - Pipeline Review, H1 2018, outlays comprehensive information on the Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4)
  • The report reviews Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics
Reasons for Purchase:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Eisai Co Ltd
  • Eli Lilly and Co
  • Ono Pharmaceutical Co Ltd
  • RaQualia Pharma Inc
  • Rottapharm Biotech Srl
  • MORE
Introduction

The Publisher's Report Coverage

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Overview

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Companies Involved in Therapeutics Development

Eisai Co Ltd

Eli Lilly and Co

Kaken Pharmaceutical Co Ltd

Ono Pharmaceutical Co Ltd

RaQualia Pharma Inc

Rottapharm Biotech Srl

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Drug Profiles

AAT-008 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CR-6086 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

E-7046 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

grapiprant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KAG-308 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ONO-4578 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

P-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize EP4 Receptor for Osteoporosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize EP4 Receptor for Inflammatory Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize Prostanoid EP2 and EP4 Receptors for Endometriosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Dormant Products

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Discontinued Products

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Product Development Milestones

Featured News & Press Releases

Sep 01, 2017: Eisai to Present Abstract on E7046 at ESMO 2017 Congress

Sep 01, 2017: Eisai to Present Abstract on its Oncology Product Candidate E7046 at the ESMO 2017 Congress

Jul 25, 2012: RaQualia Pharma Receives Allowance For EP4 Antagonist Substance Patent In Japan

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indications, H1 2018

Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Number of Products under Investigation by Universities/Institutes, H1 2018

Products under Investigation by Universities/Institutes, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by Eisai Co Ltd, H1 2018

Pipeline by Eli Lilly and Co, H1 2018

Pipeline by Kaken Pharmaceutical Co Ltd, H1 2018

Pipeline by Ono Pharmaceutical Co Ltd, H1 2018

Pipeline by RaQualia Pharma Inc, H1 2018

Pipeline by Rottapharm Biotech Srl, H1 2018

Dormant Projects, H1 2018

Discontinued Products, H1 2018

List of Figures

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Eisai Co Ltd
  • Eli Lilly and Co
  • Kaken Pharmaceutical Co Ltd
  • Ono Pharmaceutical Co Ltd
  • RaQualia Pharma Inc
  • Rottapharm Biotech Srl
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll